Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

被引：2
|
作者：
O'Reilly, Eileen Mary [1 ]
Wang, Judy Sing-Zan [2 ]
Yu, Kenneth H. [1 ]
Lowery, Maeve Aine [1 ]
Varghese, Anna M. [1 ]
Bendell, Johanna C. [3 ]
Borazanci, Erkut Hasan [4 ]
Estrella, Hayley [1 ]
Fowler, Kimberly [5 ]
Hoskins, Mariella [5 ]
Bussen, Stephanie [5 ]
Melink, Teresa J.
Kearns, Christine M.
Jun, H. Toni [5 ]
Maffuid, Paul W. [5 ]
Gutheil, John C.
Bauer, Todd Michael [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Florida Canc Specialists, Sarasota, FL USA
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] Honor Hlth, Scottsdale, AZ USA
[5] MabVax Therapeut Inc, San Diego, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-LB-B25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-B25
引用
收藏
页数：3
相关论文
共 25 条
  • [1] Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.
    O'Reilly, Eileen Mary
    Wang, Judy Sing-Zan
    Yu, Kenneth H.
    Lowery, Maeve Aine
    Varghese, Anna M.
    Bendell, Johanna C.
    Borazanci, Erkut Hasan
    Estrella, Hayley
    Fowler, Kimberly
    Hoskin, Mariella
    Jun, H. Toni
    Melink, Teresa J.
    Maffuid, Paul
    Klein, Pamela
    Gutheil, John
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies
    O'Reilly, Eileen Mary
    Borazanci, Erkut Hasan
    Yu, Kenneth H.
    Varghese, Anna M.
    Estrella, Hayley
    Kamins, David
    Melink, Teresa
    Dorr, Kirsten
    Maffuid, Paul
    Gutheil, John
    Wang, Judy Sing-Zan
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies
    O'Reilly, Eileen M.
    Bauer, Todd M.
    Infante, Jeffrey
    Gutheil, John C.
    Klein, Pamela
    Yu, Kenneth H.
    Lowery, Maeve A.
    Livingston, Phil
    Martin, Pricilla
    Scholz, Wolfgang
    Maffuid, Paul W.
    CANCER RESEARCH, 2016, 76
  • [4] Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model
    Ragupathi, Govind
    Wu, Xiaohong
    Livingston, Philip
    Scholz, Wolfgang
    Kearns, Christine
    Maffuid, Paul
    CANCER RESEARCH, 2016, 76
  • [5] First-in-Human Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive malignancies
    Lohrmann, Christian
    O'Reilly, Eileen
    ODonoghue, Joseph
    Yu, Kenneth H.
    Pandit-Taskar, Neeta
    Lyashchenko, Serge
    Ruan, Shutian
    Wu, Jiong
    DeNoble, Phillip
    Carrasquillo, Jorge
    Schmidtlein, Charles
    Teng, Rebecca
    Lowery, Maeve A.
    Varghese, Anna
    Estrella, Hayley
    Scholz, Wolfgang
    Maffuid, Paul
    Lewis, Jason
    Weber, Wolfgang
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [6] CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Sam Z. Thalji
    Mandana Kamgar
    Ben George
    Mohammed Aldakkak
    Kathleen K. Christians
    Callisia N. Clarke
    Beth A. Erickson
    William A. Hall
    Parag P. Tolat
    Zachary L. Smith
    Douglas B. Evans
    Susan Tsai
    Annals of Surgical Oncology, 2023, 30 : 3013 - 3021
  • [7] CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Thalji, Sam Z.
    Kamgar, Mandana
    George, Ben
    Aldakkak, Mohammed
    Christians, Kathleen K.
    Clarke, Callisia N.
    Erickson, Beth A.
    Hall, William A.
    Tolat, Parag P.
    Smith, Zachary L.
    Evans, Douglas B.
    Tsai, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (05) : 3013 - 3021
  • [8] Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+malignancies
    O'Reilly, Eileen A.
    Lohrmann, Christian
    O'Donoghue, Joseph A.
    Borazanci, Erkut
    Estrella, Hayley
    Teng, Rebecca
    Melink, Terri
    Dorr, Kirsten
    Kearns, Christine
    Peterson, Marvin
    Ostrowski, Jack
    Gutheil, John
    Maffuid, Paul W.
    Lewis, Jason S.
    Weber, Wolfgang
    CANCER RESEARCH, 2018, 78 (13)
  • [9] RESULTS OF A PHASE 1/2 STUDY OF NAB-PACLITAXEL PLUS GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC CANCER WITH SPARC AND CA19-9 CORRELATIVES
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T. E.
    Korn, R. L.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2010, 21 : 234 - 234
  • [10] ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer
    Sam Z. Thalji
    Mandana Kamgar
    Ben George
    Mohammed Aldakkak
    Kathleen K. Christians
    Callisia N. Clarke
    Beth A. Erickson
    William A. Hall
    Parag P. Tolat
    Zachary L. Smith
    Douglas B. Evans
    Susan Tsai
    Annals of Surgical Oncology, 2023, 30 : 3022 - 3022
123